Clinical Trials
Vitiligo Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Corticosteroids, Calcineurin Inhibitors, Psoralens and UVA (PUVA), Immunomodulators, Janus Kinase (JAK) Inhibitors, Monoclonal Antibodies, and Melanocyte-stimulating Agents; By Product Type; By Treatment Type; Key Players
Vitiligo affects nearly 1% of the entire global population. The World Vitiligo Foundation reveals that approximately 70 million have developed the condition, out of which around 20-35% are children. The prevalence rate ranges from 1-2% worldwide, with no boundaries of gender, race, or ethnicity.
Key Takeaways
- Major companies involved in the Vitiligo drugs market include Pfizer & Co., Inc., AbbVie Inc., Incyte Corporation, Reistone Biopharma Company Limited and Vyne Therapeutics Inc., among others.
- Leading drugs currently under pipeline include Upadacitinib, Povorcitinib and Afamelanotide, among others.
- The drug pipeline for vitiligo is impacted by the increased inclination of regulatory authorities like the United States FDA and EMA to offer breakthrough designations and fast-track approvals to various drugs.
Report Coverage
The Vitiligo Drug Pipeline Report by Expert Market Research gives comprehensive insights into Vitiligo drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on vitiligo.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to vitiligo are covered.
Vitiligo Drug Pipeline Outlook
Vitiligo is an autoimmune skin disorder characterized by loss of pigment from skin patches, leading to pale white spots. The condition occurs when the body’s immune system starts destroying melanocytes (skin cells that provide pigment or color). It can be categorized into several types such as generalized vitiligo (also known as nonsegmental vitiligo), segmental vitiligo, mucosal as well as focal vitiligo.
Vitiligo can affect individuals across all ages, races and genders. However, the condition is slightly more visible in people with a deeper skin tone. The treatment for vitiligo is not necessary as the condition doesn’t cause any pain or harm to the body. However, this condition can hamper the emotional well-being of an individual. Therefore, treatments like medications, light therapy, depigmentation therapy, and surgery are available. In medications, corticosteroids, topical Janus kinase inhibitors (ruxolitinib) and calcineurin inhibitors are amongst the common drug classes.
In June 2024, the United States FDA approved the first JAK inhibitor called Ruxolitinib (Opzelura). It is applied directly to the affected areas and has fewer side effects in comparison to the oral medicines available.
Vitiligo – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of vitiligo drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
- Corticosteroids
- Calcineurin Inhibitors
- Psoralens and UVA (PUVA)
- Immunomodulators
- Janus Kinase (JAK) Inhibitors
- Monoclonal Antibodies
- Melanocyte-stimulating Agents
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Topical
- Others
Vitiligo – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. EMR analysis shows phase II covers a major share of the total clinical trials conducted, with over 50 drugs in the pipeline.
Vitiligo – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under vitiligo pipeline analysis include corticosteroids, calcineurin inhibitors, psoralens, and UVA (PUVA), immunomodulators, Janus kinase (JAK) inhibitors, monoclonal antibodies, and melanocyte-stimulating agents, among others. Corticosteroids like Clobetasol Propionate and Betamethasone Valerate are used to reduce inflammation and stimulate pigment production. Calcineurin inhibitors are specifically designed for sensitive areas such as the face and groin. Janus kinase (JAK) inhibitors are a relatively newer class of drugs that inhibit the pathway of immune response.
The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
Vitiligo Clinical Trials Assessment – Competitive Dynamics
The EMR report for the vitiligo drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vitiligo clinical trials:
- Pfizer & Co., Inc.
- AbbVie Inc.
- Incyte Corporation
- Reistone Biopharma Company Limited
- Vyne Therapeutics Inc.
- Others
Vitiligo – Pipeline Drugs Profile
Upadacitinib
This drug is part of Phase 2b multicenter, randomized, double-blind, placebo-controlled study for nonsegmental vitiligo. Developed by AbbVie Inc., Upadacitinib showed positive results for over 70% of the participants. At week 52, the cohort which was receiving an 11mg dosage showed a 63% improvement in facial vitiligo (F-VASI)
Povorcitinib
It is an oral small-molecule JAK1 inhibitor, investigated for its efficacy and safety on adult patients with extensive nonsegmental vitiligo. Povorcitinib is currently in a Phase 2b randomized, double-blind, placebo-controlled, dose-ranging clinical trial. It has been well tolerated in patients.
Afamelanotide
Afamelanotide (SCENESSE®, Clinuvel Pharmaceuticals) is a potential drug alternative for vitiligo. It is an alpha-melanocyte-stimulating hormone (αMSH) analogue and works by regulating the production of eumelanin (a form of melanin). The drug is being investigated as a monotherapy in CUV104, a new clinical study.
Reasons To Buy This Report
The Vitiligo Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Vitiligo. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Key Questions Answered in the Vitiligo – Pipeline Assessment Report
- What is the current landscape of vitiligo pipeline drugs?
- How many companies are developing vitiligo drugs?
- How many phase III and phase IV drugs are currently present in vitiligo pipeline drugs?
- Which companies/institutions are leading the vitiligo drug development?
- What is the efficacy and safety profile of vitiligo pipeline drugs?
- What are the opportunities and challenges present in the vitiligo drug pipeline landscape?
- Which company is conducting major trials for vitiligo drugs?
- What are the geographies covered for clinical trials in vitiligo?
- What are emerging trends in vitiligo clinical trials?
Related Reports
Global Vitiligo Treatment Market
Global Monoclonal Antibodies Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Vitiligo
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Vitiligo: Epidemiology Snapshot
5.1 Vitiligo Incidence by Key Markets
5.2 Vitiligo– Patients Seeking Treatment in Key Markets
6 Vitiligo: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Vitiligo: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Vitiligo, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Vitiligo Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Vitiligo Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Ritlecitinib
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Upadacitinib
10.2.3 Ruxolitinib
10.2.4 Other Drug
11 Vitiligo Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 SHR0302
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 VYN201
11.2.3 Other Drugs
12 Vitiligo Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Abatacept
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Vitiligo Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Vitiligo, Key Drug Pipeline Companies
14.1 Pfizer & Co., Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AbbVie Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Incyte Corporation
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Reistone Biopharma Company Limited
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Vyne Therapeutics Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
Purchase Options
Call us
Purchase Full Report
Datasheet
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2499
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3499
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4499
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER